Authorship Contributions JCO Journals adhere to the guidelines on authorship established by the International Committee of Medical Journal Editors (ICMJE) statement on the role of Authors and ...

Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, typically resulting in a median survival of 12–15 months. Epidermal growth factor receptor (EGFR) alterations, ...

Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of ...

This is a retrospective, observational study using data from the National Cancer Database from 2004 to 2015. The database was queried for newly diagnosed patients with cancer stages I-IV who had TTI ...

View the current volume of the ASCO Educational Book ...

Clinical practice guidelines serve as a guide for doctors and outline appropriate methods of treatment and care. Guidelines can address specific clinical situations (disease-oriented) or use of ...

A literature search was conducted for randomized controlled trials that met the selection criteria of the original guideline 1 published between January 1, 2020, and October 15, 2024, that were not ...

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth factor ...

The discovery of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) has profoundly reshaped treatment paradigms over the past two decades. 1 - 3 While common ...

Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...

Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point ...